Iniparib (BSI-201 or 4-iodo-3-nitrosobenzamide) inactivated poly(ADP-ribose) polymerase by zinc ejection from the first zinc finger of this nuclear protein. Iniparib, either alone or in combination with chemotherapy, had significant antitumor activity in preclinical studies in vitro and in vivo. In June 2013, Sanofi dropped the drug after it failed in a phase III trial of patients with squamous non–small-cell lung cancer and a phase II trial in platinum-resistant ovarian cancer.

Frakefamide is a tetrapeptide with an amide function at the C-terminus. The amino acid sequence of frakefamide is L-tyrosyl-D-alanyl-p-fluoro-L-phenylalanyl-Lphenylalaninamide. Hence, it contains both natural and unnatural R-amino acids. Frakefamide has shown interesting properties for use in acute and chronic pain treatment. It acts as a selective agonist on mu-opioid receptors and belongs to the dermorphin peptide family. It has been shown to be a potent peripherally acting analgesic in rats and humans. However, frakefamide had been found to have "unexpected results" in Phase II trials and AstraZeneca offered to hand the drug back.

Telinavir (previously known as SC-52151) was developed as an anti-HIV aspartyl protease inhibitor for the treatment of HIV Infections. Telinavir participated in Phase I/II clinical study. In spite of the drug was well tolerated no antiviral activity was produced and further development of the drug was discontinued.

ISOPROPICILLIN is semisynthetic penicillin.

Fubromegan, a ganglionic blocking agent as an iodide salt, FUBROGONIUM IODIDE was used in Russia in patients with peptic ulcer and in the symptomatic therapy of patients with pneumoconioses. The antispasmodic effect of fubromegan was due to the effect on m- and n-cholinergic structures of smooth muscles and ganglia.

Octicizer is used as a plasticizer.

Menarini was developing oral nepadutant (MEN 11420), a potent and selective tachykinin neurokinin-2 receptor antagonist, for the treatment of infant colic. Nepadutant has been used in trials studying the treatment of colic, infantile colic, and infantile functional gastrointestinal disorders. MEN 11420 is a glycosylated derivative of the potent, selective, conformationally-constrained tachykinin NK2 receptor antagonist MEN 10627. MEN 11420 competitively bound with high affinity to the human NK2 receptor stably transfected in CHO cells, displacing radiolabelled [125I]-neurokinin A and [3H]-SR 48968 with Ki values of 2.5+/-0.7 nM (n = 6) and 2.6+/-0.4 nM (n = 3), respectively.

Benorterone (or SKF 7690), a steroidal antiandrogen that was studied in the treatment of acne, seborrhea, and hirsutism in women but was never marketed.